GLAXOSMITHKLINE PLC

GSK
Delayed Quote. Delayed  - 04/15 11:35:28 am
1348.4GBX +4.56%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 34 09933 651
EBITDA1 9 5309 657
Operating profit (EBIT)1 8 9068 184
Operating Margin 26,1%24,3%
Pre-Tax Profit (EBT)1 6 9685 897
Net income1 5 7493 807
Net margin 16,9%11,3%
EPS2 1,140,77
Dividend per Share2 0,800,80
Last update 02/03/202104/15/2021
1 GBP in Million
2 GBP
Estimates
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 20 78021 383
Net Cash position1 --
Leverage (Debt / EBITDA) 2,18x2,21x
Free Cash Flow1 5 4064 442
ROE (Net Profit / Equities) 44,4%34,2%
Shareholders' equity1 12 95111 124
ROA (Net Profit / Asset) 7,18%4,80%
Assets1 80 06279 349
Book Value Per Share2 2,933,02
Cash Flow per Share2 1,681,23
Capex1 1 2261 426
Capex / Sales 3,60%4,24%
Last update 02/03/202104/15/2021
1 GBP in Million
2 GBP
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 67 183 M GBP -
Entreprise Value (EV) 88 566 M GBP 87 217 M GBP
Valuation 2021e 2022e
P/E ratio (Price / EPS) 17,4x 14,9x
Capitalization / Revenue 2,00x 1,90x
EV / Revenue 2,63x 2,51x
EV / EBITDA 9,17x 8,40x
Yield (DPS / Price) 5,90% 4,48%
Price to book (Price / BVPS) 4,46x 4,23x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 24,3% 25,5%
Operating Leverage (Delta EBIT / Delta Sales) -6,16x 2,00x
Net Margin (Net Profit / Revenue) 11,3% 12,8%
ROA (Net Profit / Asset) 4,80% 5,40%
ROE (Net Profit / Equities) 34,2% 35,3%
Rate of Dividend 103% 66,8%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   4,24% 4,11%
Cash Flow / Sales 18,2% 20,2%
Capital Intensity (Assets / Sales) 2,36x 2,38x
Financial Leverage (Net Debt / EBITDA) 2,21x 1,90x
Price Earning Ratio
EPS & Dividend